WallStreetZenWallStreetZen

NASDAQ: BDSX
Biodesix Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BDSX

Based on 1 analyst offering 12 month price targets for Biodesix Inc

Min Forecast
$20.00+154.13%
Avg Forecast
$20.00+154.13%
Max Forecast
$20.00+154.13%

Should I buy or sell BDSX stock?

Based on 1 analyst offering ratings for Biodesix Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although BDSX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates BDSX as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their BDSX stock forecasts and price targets.

BDSX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-09-19

1 of 1

Forecast return on equity

Is BDSX forecast to generate an efficient return?

Forecast return on assets

Is BDSX forecast to generate an efficient return on assets?

Company
-17.56%
Industry
12.18%
BDSX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BDSX earnings per share forecast

What is BDSX's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$5.51
Avg 2 year Forecast
-$3.55
Avg 3 year Forecast
-$1.96

BDSX revenue forecast

What is BDSX's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$84.9M+5.9%
Avg 2 year Forecast
$107.3M+33.85%
Avg 3 year Forecast
$130.4M+62.6%
BDSX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BDSX revenue growth forecast

How is BDSX forecast to perform vs Diagnostics & Research companies and vs the US market?

Company
15.8%
Industry
4.65%
Market
58.25%
BDSX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BDSX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BDSX vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
BDSX$7.87$20.00+154.13%Strong Buy
DRIO$11.97N/AN/A
PRPO$23.75N/AN/A
VNRX$0.31$3.17+918.33%Strong Buy
FONR$14.07N/AN/A
View Top Diagnostic & Research Stocks

Biodesix Stock Forecast FAQ

Is Biodesix Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: BDSX) stock is to Strong Buy BDSX stock.

Out of 1 analyst, 1 (100%) are recommending BDSX as a Strong Buy, 0 (0%) are recommending BDSX as a Buy, 0 (0%) are recommending BDSX as a Hold, 0 (0%) are recommending BDSX as a Sell, and 0 (0%) are recommending BDSX as a Strong Sell.

If you're new to stock investing, here's how to buy Biodesix stock.

What is BDSX's earnings growth forecast for 2025-2027?

(NASDAQ: BDSX) Biodesix's forecast annual earnings growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 20.44%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 104.66%.

Biodesix's earnings in 2025 is -$39,536,000.On average, 7 Wall Street analysts forecast BDSX's earnings for 2025 to be -$43,819,913, with the lowest BDSX earnings forecast at -$45,220,114, and the highest BDSX earnings forecast at -$36,755,265. On average, 7 Wall Street analysts forecast BDSX's earnings for 2026 to be -$28,239,499, with the lowest BDSX earnings forecast at -$35,864,228, and the highest BDSX earnings forecast at -$23,389,714.

In 2027, BDSX is forecast to generate -$15,580,414 in earnings, with the lowest earnings forecast at -$15,593,143 and the highest earnings forecast at -$15,370,383.

What is BDSX's revenue growth forecast for 2025-2027?

(NASDAQ: BDSX) Biodesix's forecast annual revenue growth rate of 15.8% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 4.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.25%.

Biodesix's revenue in 2025 is $80,173,000.On average, 7 Wall Street analysts forecast BDSX's revenue for 2025 to be $675,445,612, with the lowest BDSX revenue forecast at $631,522,275, and the highest BDSX revenue forecast at $710,044,886. On average, 7 Wall Street analysts forecast BDSX's revenue for 2026 to be $853,724,557, with the lowest BDSX revenue forecast at $760,165,702, and the highest BDSX revenue forecast at $933,917,862.

In 2027, BDSX is forecast to generate $1,037,103,097 in revenue, with the lowest revenue forecast at $956,671,121 and the highest revenue forecast at $1,110,215,842.

What is BDSX's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: BDSX) forecast ROA is -17.56%, which is lower than the forecast US Diagnostics & Research industry average of 12.18%.

What is BDSX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year BDSX price target, the average BDSX price target is $20.00, with the highest BDSX stock price forecast at $20.00 and the lowest BDSX stock price forecast at $20.00.

The Wall Street analyst predicted that Biodesix's share price could reach $20.00 by Sep 19, 2026. The average Biodesix stock price prediction forecasts a potential upside of 154.13% from the current BDSX share price of $7.87.

What is BDSX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: BDSX) Biodesix's current Earnings Per Share (EPS) is -$5.36. On average, analysts forecast that BDSX's EPS will be -$5.51 for 2025, with the lowest EPS forecast at -$5.68, and the highest EPS forecast at -$4.62. On average, analysts forecast that BDSX's EPS will be -$3.55 for 2026, with the lowest EPS forecast at -$4.51, and the highest EPS forecast at -$2.94. In 2027, BDSX's EPS is forecast to hit -$1.96 (min: -$1.96, max: -$1.93).

What is BDSX's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: BDSX) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.